Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC reduced its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 8.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 920 shares of the company’s stock after selling 88 shares during the period. Nisa Investment Advisors LLC’s holdings in Krystal Biotech were worth $166,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Crossmark Global Holdings Inc. increased its holdings in Krystal Biotech by 2.7% during the 1st quarter. Crossmark Global Holdings Inc. now owns 2,370 shares of the company’s stock worth $427,000 after purchasing an additional 63 shares during the last quarter. Summit Investment Advisors Inc. grew its stake in Krystal Biotech by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company’s stock worth $407,000 after buying an additional 82 shares during the last quarter. New York State Teachers Retirement System grew its stake in Krystal Biotech by 0.6% during the 1st quarter. New York State Teachers Retirement System now owns 15,979 shares of the company’s stock worth $2,881,000 after buying an additional 100 shares during the last quarter. Fifth Third Bancorp boosted its position in Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock worth $31,000 after acquiring an additional 105 shares during the period. Finally, Envestnet Asset Management Inc. boosted its position in Krystal Biotech by 1.1% during the 4th quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company’s stock worth $1,822,000 after acquiring an additional 121 shares during the period. 86.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on KRYS. Chardan Capital reissued a “buy” rating and set a $219.00 price target on shares of Krystal Biotech in a research report on Wednesday, May 7th. Citigroup restated a “neutral” rating and set a $176.00 price target (up previously from $155.00) on shares of Krystal Biotech in a report on Wednesday, July 9th. HC Wainwright restated a “buy” rating and set a $240.00 price target on shares of Krystal Biotech in a report on Tuesday, June 24th. Finally, Guggenheim decreased their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $213.75.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 13,435 shares of the business’s stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $150.30, for a total value of $2,019,280.50. Following the sale, the insider directly owned 1,443,276 shares in the company, valued at approximately $216,924,382.80. The trade was a 0.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders have sold 49,800 shares of company stock worth $7,487,943. 13.70% of the stock is owned by insiders.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS opened at $150.15 on Friday. Krystal Biotech, Inc. has a 1 year low of $122.80 and a 1 year high of $219.34. The company has a 50 day simple moving average of $136.27 and a 200 day simple moving average of $156.00. The firm has a market cap of $4.34 billion, a PE ratio of 36.09 and a beta of 0.67.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. The company had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million. As a group, research analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).